PDCD1 and gastric cancer: According to the result of randomized KEYNOTE-062 trial, the large international CheckMate-649 trial and the randomized ATTRACTION-4 trial, Asian patients exhibited better clinical benefits from anti-PD-1/PD-L1 therapy compared with North American and European patients, which is most likely related to a higher rate of H. pylori infection in Asian GC patients (41).